Corticosteroid therapy in patients with severe COVID-19

Detalhes bibliográficos
Autor(a) principal: Dantas, Thiago Costa de Araújo
Data de Publicação: 2021
Outros Autores: Gomes, Andriny Cunha Apoliano, Lima, Ikaro Peixoto Correia, Lucas , Beatriz Bispo, Aguiar, Mateus Rodrigues de, Cavalcanti, Taiza Carvalho de Holanda, Pinheiro, Francisco Irochima, Rêgo, Amália Cinthia Meneses, Araújo-Filho, Irami
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/12114
Resumo: The world panorama of disseminating the new coronavirus SARS-CoV-2 is considered a pandemic by the World Health Organization (WHO) with the risk of complications due to the imbalance of immune responses. The present study evaluated whether the use of corticosteroids has scientifically proven efficacy in treating patients with the severe form of COVID-19. It was a cross-sectional and integrative literature review from December 2019 to November 2020 after researching the PubMed, Scopus, Embase, Web of Science, and Google Scholar databases. According to the studies analyzed, positive results of corticotherapy were observed in patients with SARS-CoV-2 in the severe form of the disease. It was concluded that steroids are not indicated in the mild form of COVID-19 unless they have other comorbidities, such as chronic obstructive pulmonary disease (COPD) or asthma. Glucocorticoid therapy is relevant in the severe form of SARS-CoV-2, with short-term management and low doses being beneficial. It reduces morbidity and mortality and the length of stay in the ICU.
id UNIFEI_9968fa6e2dde606a9bd5061e3e97b520
oai_identifier_str oai:ojs.pkp.sfu.ca:article/12114
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Corticosteroid therapy in patients with severe COVID-19Terapia con corticosteroides en pacientes con COVID-19 graveTerapia com corticosteroides em pacientes com COVID-19 graveInfecções por coronavírusCOVID-19SARS-CoV-2CorticosteroidesTerapiaTerapêutica.Coronavirus infectionsCOVID-19SARS-CoV-2CorticosteroidsTherapyTherapeutics.Infecciones por coronavirusCOVID-19SARS-CoV-2CorticosteroidesTerapiaTerapéutica.The world panorama of disseminating the new coronavirus SARS-CoV-2 is considered a pandemic by the World Health Organization (WHO) with the risk of complications due to the imbalance of immune responses. The present study evaluated whether the use of corticosteroids has scientifically proven efficacy in treating patients with the severe form of COVID-19. It was a cross-sectional and integrative literature review from December 2019 to November 2020 after researching the PubMed, Scopus, Embase, Web of Science, and Google Scholar databases. According to the studies analyzed, positive results of corticotherapy were observed in patients with SARS-CoV-2 in the severe form of the disease. It was concluded that steroids are not indicated in the mild form of COVID-19 unless they have other comorbidities, such as chronic obstructive pulmonary disease (COPD) or asthma. Glucocorticoid therapy is relevant in the severe form of SARS-CoV-2, with short-term management and low doses being beneficial. It reduces morbidity and mortality and the length of stay in the ICU.El panorama mundial de diseminación del nuevo coronavirus SARS-CoV-2 es considerado una pandemia por la Organización Mundial de la Salud (OMS) con riesgo de complicaciones por el desequilibrio de las respuestas inmunes. El presente estudio evaluó si el uso de corticosteroides tiene eficacia científicamente probada en el tratamiento de pacientes con la forma grave de COVID-19. Se realizó una revisión transversal e integradora de la literatura de diciembre de 2019 a noviembre de 2020 tras consultar las bases de datos PubMed, Scopus, Embase, Web of Science y Google Scholar. Según los estudios analizados, se observaron resultados positivos de la corticoterapia en pacientes con SARS-CoV-2 en la forma grave de la enfermedad. Se concluyó que los esteroides no están indicados para la forma leve de COVID-19 a menos que existan otras comorbilidades, como enfermedad pulmonar obstructiva crónica (EPOC) o asma. La terapia con glucocorticoides es relevante en la forma grave de SARS-CoV-2, siendo beneficioso el tratamiento a corto plazo y las dosis bajas. Reduce la morbilidad, mortalidad y el tiempo de estancia en la UCI.O panorama mundial da disseminação do novo coronavírus SARS-CoV-2 é considerado uma pandemia pela Organização Mundial da Saúde (OMS) com risco de complicações devido ao desequilíbrio das respostas imunológicas. O presente estudo avaliou se o uso de corticosteroides tem eficácia cientificamente comprovada no tratamento de pacientes com a forma grave de COVID-19. Realizou-se uma revisão transversal e integrativa da literatura de dezembro de 2019 a novembro de 2020, após pesquisa nas bases de dados PubMed, Scopus, Embase, Web of Science e Google Scholar. De acordo com os estudos analisados, resultados positivos da corticoterapia foram observados em pacientes com SARS-CoV-2 na forma grave da doença. Concluiu-se que os esteroides não são indicados na forma leve de COVID-19, a menos que existam outras comorbidades, como doença pulmonar obstrutiva crônica (DPOC) ou asma. A terapia com glicocorticoides é relevante na forma grave da SARS-CoV-2, com o manejo de curto prazo e baixas doses sendo benéficos. Reduz a morbidade, mortalidade e o tempo de permanência na UTI.Research, Society and Development2021-01-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1211410.33448/rsd-v10i1.12114Research, Society and Development; Vol. 10 No. 1; e58910112114Research, Society and Development; Vol. 10 Núm. 1; e58910112114Research, Society and Development; v. 10 n. 1; e589101121142525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/12114/10891Copyright (c) 2021 Thiago Costa de Araújo Dantas; Andriny Cunha Apoliano Gomes; Ikaro Peixoto Correia Lima; Beatriz Bispo Lucas ; Mateus Rodrigues de Aguiar; Taiza Carvalho de Holanda Cavalcanti; Francisco Irochima Pinheiro; Amália Cinthia Meneses Rêgo; Irami Araújo-Filhohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessDantas, Thiago Costa de Araújo Gomes, Andriny Cunha Apoliano Lima, Ikaro Peixoto Correia Lucas , Beatriz Bispo Aguiar, Mateus Rodrigues de Cavalcanti, Taiza Carvalho de Holanda Pinheiro, Francisco Irochima Rêgo, Amália Cinthia Meneses Araújo-Filho, Irami2021-02-20T21:19:23Zoai:ojs.pkp.sfu.ca:article/12114Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:33:46.828523Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Corticosteroid therapy in patients with severe COVID-19
Terapia con corticosteroides en pacientes con COVID-19 grave
Terapia com corticosteroides em pacientes com COVID-19 grave
title Corticosteroid therapy in patients with severe COVID-19
spellingShingle Corticosteroid therapy in patients with severe COVID-19
Dantas, Thiago Costa de Araújo
Infecções por coronavírus
COVID-19
SARS-CoV-2
Corticosteroides
Terapia
Terapêutica.
Coronavirus infections
COVID-19
SARS-CoV-2
Corticosteroids
Therapy
Therapeutics.
Infecciones por coronavirus
COVID-19
SARS-CoV-2
Corticosteroides
Terapia
Terapéutica.
title_short Corticosteroid therapy in patients with severe COVID-19
title_full Corticosteroid therapy in patients with severe COVID-19
title_fullStr Corticosteroid therapy in patients with severe COVID-19
title_full_unstemmed Corticosteroid therapy in patients with severe COVID-19
title_sort Corticosteroid therapy in patients with severe COVID-19
author Dantas, Thiago Costa de Araújo
author_facet Dantas, Thiago Costa de Araújo
Gomes, Andriny Cunha Apoliano
Lima, Ikaro Peixoto Correia
Lucas , Beatriz Bispo
Aguiar, Mateus Rodrigues de
Cavalcanti, Taiza Carvalho de Holanda
Pinheiro, Francisco Irochima
Rêgo, Amália Cinthia Meneses
Araújo-Filho, Irami
author_role author
author2 Gomes, Andriny Cunha Apoliano
Lima, Ikaro Peixoto Correia
Lucas , Beatriz Bispo
Aguiar, Mateus Rodrigues de
Cavalcanti, Taiza Carvalho de Holanda
Pinheiro, Francisco Irochima
Rêgo, Amália Cinthia Meneses
Araújo-Filho, Irami
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Dantas, Thiago Costa de Araújo
Gomes, Andriny Cunha Apoliano
Lima, Ikaro Peixoto Correia
Lucas , Beatriz Bispo
Aguiar, Mateus Rodrigues de
Cavalcanti, Taiza Carvalho de Holanda
Pinheiro, Francisco Irochima
Rêgo, Amália Cinthia Meneses
Araújo-Filho, Irami
dc.subject.por.fl_str_mv Infecções por coronavírus
COVID-19
SARS-CoV-2
Corticosteroides
Terapia
Terapêutica.
Coronavirus infections
COVID-19
SARS-CoV-2
Corticosteroids
Therapy
Therapeutics.
Infecciones por coronavirus
COVID-19
SARS-CoV-2
Corticosteroides
Terapia
Terapéutica.
topic Infecções por coronavírus
COVID-19
SARS-CoV-2
Corticosteroides
Terapia
Terapêutica.
Coronavirus infections
COVID-19
SARS-CoV-2
Corticosteroids
Therapy
Therapeutics.
Infecciones por coronavirus
COVID-19
SARS-CoV-2
Corticosteroides
Terapia
Terapéutica.
description The world panorama of disseminating the new coronavirus SARS-CoV-2 is considered a pandemic by the World Health Organization (WHO) with the risk of complications due to the imbalance of immune responses. The present study evaluated whether the use of corticosteroids has scientifically proven efficacy in treating patients with the severe form of COVID-19. It was a cross-sectional and integrative literature review from December 2019 to November 2020 after researching the PubMed, Scopus, Embase, Web of Science, and Google Scholar databases. According to the studies analyzed, positive results of corticotherapy were observed in patients with SARS-CoV-2 in the severe form of the disease. It was concluded that steroids are not indicated in the mild form of COVID-19 unless they have other comorbidities, such as chronic obstructive pulmonary disease (COPD) or asthma. Glucocorticoid therapy is relevant in the severe form of SARS-CoV-2, with short-term management and low doses being beneficial. It reduces morbidity and mortality and the length of stay in the ICU.
publishDate 2021
dc.date.none.fl_str_mv 2021-01-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/12114
10.33448/rsd-v10i1.12114
url https://rsdjournal.org/index.php/rsd/article/view/12114
identifier_str_mv 10.33448/rsd-v10i1.12114
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/12114/10891
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 1; e58910112114
Research, Society and Development; Vol. 10 Núm. 1; e58910112114
Research, Society and Development; v. 10 n. 1; e58910112114
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052817229217792

Registros relacionados